Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003Astri Fjelde Maaland, Jostein Dahle, Véronique Pascal et al.|European Journal of Nuclear Medicine and Molecular Imaging|2019Cited by 16
B-Cell Targeting Anti-CD37 Humanized Antibodies Engineered for Potent Effector Functions and Extended Plasma Half-LifeElisa Fiorito, Jostein Dahle, Roman Generalov et al.|Blood|2022Cited by 0
NNV024, a Humanized Anti-CD37 Antibody with Enhanced ADCC and Extended Plasma Half-Life for the Treatment of B-Cell MalignanciesRoman Generalov, Jostein Dahle, Elisa Fiorito et al.|Blood|2022Cited by 0
NNV024, a novel humanized anti-CD37 antibody with enhanced ADCC and prolonged plasma half-life in human FcRn transgenic mice for treatment of NHLRoman Generalov, Jostein Dahle, Sigrid S. Skånland et al.|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 0